462 related articles for article (PubMed ID: 26940689)
1. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
Corli O; Floriani I; Roberto A; Montanari M; Galli F; Greco MT; Caraceni A; Kaasa S; Dragani TA; Azzarello G; Luzzani M; Cavanna L; Bandieri E; Gamucci T; Lipari G; Di Gregorio R; Valenti D; Reale C; Pavesi L; Iorno V; Crispino C; Pacchioni M; Apolone G;
Ann Oncol; 2016 Jun; 27(6):1107-1115. PubMed ID: 26940689
[TBL] [Abstract][Full Text] [Related]
2. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K
BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
Leppert W; Nosek K
Curr Pharm Des; 2019; 25(30):3216-3224. PubMed ID: 31333114
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial.
Zecca E; Brunelli C; Bracchi P; Biancofiore G; De Sangro C; Bortolussi R; Montanari L; Maltoni M; Moro C; Colonna U; Finco G; Roy MT; Ferrari V; Alabiso O; Rosti G; Kaasa S; Caraceni A
J Pain Symptom Manage; 2016 Dec; 52(6):783-794.e6. PubMed ID: 27742577
[TBL] [Abstract][Full Text] [Related]
7. Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
[TBL] [Abstract][Full Text] [Related]
8. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
9. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.
Wiffen PJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD011056. PubMed ID: 24874470
[TBL] [Abstract][Full Text] [Related]
10. Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement.
Joppich R; Richards P; Kelen R; Stern W; Zarghooni K; Otto C; Böhmer A; Petzke F; Treptau T; Lefering R; Bäthis H; Neugebauer E
Clin Ther; 2012 Aug; 34(8):1751-60. PubMed ID: 22795613
[TBL] [Abstract][Full Text] [Related]
11. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids.
Mystakidou K; Befon S; Tsilika E; Dardoufas K; Georgaki S; Vlahos L
Oncology; 2002; 62(1):9-16. PubMed ID: 11810038
[TBL] [Abstract][Full Text] [Related]
12. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
[TBL] [Abstract][Full Text] [Related]
13. Oral oxycodone for pain after caesarean section: A randomized comparison with nurse-administered IV morphine in a pragmatic study.
Niklasson B; Arnelo C; Öhman SG; Segerdahl M; Blanck A
Scand J Pain; 2015 Apr; 7(1):17-24. PubMed ID: 29911601
[TBL] [Abstract][Full Text] [Related]
14. Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study.
Lee KH; Kang JH; Oh HS; Choi MK; Shim BY; Eum YJ; Park HJ; Kang JH
Pain Res Manag; 2017; 2017():9741729. PubMed ID: 29670416
[TBL] [Abstract][Full Text] [Related]
15. The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
Kim DY; Song HS; Ahn JS; Ryoo BY; Shin DB; Yim CY; Kim SY
Support Care Cancer; 2010 Feb; 19(2):297-301. PubMed ID: 20213238
[TBL] [Abstract][Full Text] [Related]
16. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine.
Kalso E; Simpson KH; Slappendel R; Dejonckheere J; Richarz U
BMC Med; 2007 Dec; 5():39. PubMed ID: 18154644
[TBL] [Abstract][Full Text] [Related]
17. Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain.
Richards P; Riff D; Kelen R; Stern W;
J Opioid Manag; 2011; 7(3):217-28. PubMed ID: 21823552
[TBL] [Abstract][Full Text] [Related]
18. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
Kuo A; Wyse BD; Meutermans W; Smith MT
Br J Pharmacol; 2015 Jan; 172(2):532-48. PubMed ID: 24641546
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
20. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
